Tata 1mg likely to get $200 mn booster shot; Novo, CPPIB, Permira and ChrysCap line up

Novo Holdings, CPPIB, Permira, and ChrysCapital have shown interest in investing in Tata Group’s online pharmacy 1mg, which seeks up to $200 million for its next growth phase. The investors, however, consider the $1.25 billion 2022 valuation too high, proposing $750–800 million instead. Some also want board seats, which Tata is unwilling to offer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtG0F8J
via IFTTT